TTP spin-out aims to fill market gap for scalable gene therapies

Cellular Origins’ proprietary technology will enable the commercial manufacture of advanced therapies in late-stage development, without the requirement for process change. The company states its solution for automated sterile fluidic interconnection can adapt and link bioprocess equipment, to permit full automation of current cell therapy manufacturing and future innovation of new processes.

Cell and gene therapy have seen rapid expansion. Some 64 new cell and gene therapies are predicted for approval with the market expected to top US$90bn (CAGR 22%) by 2030, cites the firm. 

Achieving scalable and cost-effective manufacture of therapies has proven more challenging for the industry however, with Cellular Origins hoping to address demand. 

The firm boasts life science, robotics and engineering industry expertise with TTP backing which it plans to harness for the development of a proprietary automation platform for advanced therapy manufacture.

Its objective is to use this to bring developers’ therapies to market and boost patient access to the very latest cell and gene therapies.

TTP Head of Life Sciences Matthew Carr said: “For over 30 years, TTP has worked with some of the world’s most innovative and ambitious biotech companies, developing new tools and technologies.

“We have every confidence that Cellular Origins will deliver on its mission to address the urgent need for scalable, cost-effective and efficient manufacture of cell and gene therapies, enabling many more patients to benefit from the very latest advances in cell therapy.”